DHA Supplementation and Pregnancy Outcome
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to determine if increasing DHA intake during pregnancy can increase gestation duration and enhance infant and childhood outcomes related to visual acuity, stereoacuity, attention, and distractibility.
| Condition | Intervention | Phase |
|---|---|---|
|
Pregnancy |
Drug: DHA Other: Placebo capsule |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Kansas University DHA Outcome Study (KUDOS) |
- Gestation duration, birth weight, length and head circumference, infant and child visual acuity, Stereoacuity, attention, problem solving, memory, global development, distractibility [ Time Frame: 4 years ] [ Designated as safety issue: No ]
- Infant growth throughout infancy and toddlerhood [ Time Frame: 4 years ] [ Designated as safety issue: No ]
| Enrollment: | 350 |
| Study Start Date: | January 2006 |
| Study Completion Date: | October 2011 |
| Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
DHA capsule
|
Drug: DHA
600 mg DHA
Other Name: docosahexaenoic acid
|
|
Placebo Comparator: 2
Placebo capsule
|
Other: Placebo capsule
Placebo capsule
|
Detailed Description:
Although numerous trials show benefits of postnatal DHA supplementation for visual acuity and others show benefits for cognitive function and/or attention, studies of increased DHA exposure during fetal life are needed, especially in the US. Women in the US consume low amounts of DHA compared to other world populations, and this likely means less DHA transfer to the fetus than in many other populations. Prenatal DHA exposure may be more important than postnatal exposure, because animal studies show critical windows for brain DHA accumulation in relation to effects on neurotransmitters such as serotonin, dopamine and GABA.
Eligibility| Ages Eligible for Study: | 16 Years to 36 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Pregnant 8-20 wks at enrollment
- single fetus
- BMI <40
Exclusion Criteria:
- diabetes (Type I, ii, GDM)
- hypertension (primary, PIH, preeclampsia/eclampsia)
Contacts and Locations| United States, Kansas | |
| University of Kansas Medical Center | |
| Kansas City, Kansas, United States, 66160 | |
| United States, Missouri | |
| Truman Medical Center | |
| Kansas City, Missouri, United States, 64108 | |
| Principal Investigator: | Susan E Carlson, PhD | University of Kansas |
| Principal Investigator: | John Colombo, PhD | University of Kansas |
More Information
No publications provided by University of Kansas
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Susan Carlson, PhD, Professor, University of Kansas Medical Center Research Institute |
| ClinicalTrials.gov Identifier: | NCT00266825 History of Changes |
| Other Study ID Numbers: | 10186, R01HD047315 |
| Study First Received: | December 15, 2005 |
| Last Updated: | June 18, 2012 |
| Health Authority: | United States: Food and Drug Administration |
ClinicalTrials.gov processed this record on May 21, 2013